Floatz logo

tt125-802

Adult Solid Tumor

TOLREMO therapeutics AGPhase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Adult Solid Tumor cohort.

Asset / SponsorPhaseRating
Pembrolizumab
CatalYm GmbH
Phase 2BB
Docetaxel
CatalYm GmbH
Phase 3B
Nivolumab
CatalYm GmbH
Phase 2B
Crofelemer
Napo Pharmaceuticals, Inc.
Phase 3B
Tazemetostat
Institut Bergonié
Phase 2B

View all 31 →

Same molecule, other indications

tt125-802 is also rated in:

Adult DiseaseDormant
CC
Indicative ·
47 / 100
View asset →
squamous cell lung carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
KRAS G12CDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →